{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058730","form_type":"8-K","ticker":"CALC","cik":"0001534133","company_name":"CalciMedica, Inc.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.878043+00:00","generated_at":"2026-06-02T02:17:01.430356+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CalciMedica Q1 net income $0.1M; CARPO Phase 2b enrollment completed; cash into 2H 2025","bullets":["Net income of $0.1M ($0.01/share) driven by $5.6M non-cash gain on warrant liability, offsetting $5.8M operating loss.","Cash & equivalents $25.7M as of March 31, 2024; expected to fund operations into second half of 2025.","Phase 2b CARPO trial (Auxora in acute pancreatitis) fully enrolled at 216 patients; topline data expected in Q2 2024.","Phase 2 KOURAGE trial (Auxora in severe AKI with respiratory failure) cleared by FDA; first patient enrollment expected Q2 2024.","Private placement raised up to ~$54M ($20.4M upfront, ~$33.1M warrants) to support ongoing and planned trials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058730","json":"https://secwatch.observer/filing/0000950170-24-058730.json","markdown":"https://secwatch.observer/filing/0000950170-24-058730.md","text":"https://secwatch.observer/filing/0000950170-24-058730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024058730/0000950170-24-058730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024058730/calc-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:17:01.430356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25821f1260f103955542ecdf2a325aa117bc1624","claim":"CalciMedica, Inc. reported the first quarter ended March 31, 2024 results: net income $0.1 million, EPS $0.01 per share (basic and diluted).","evidence_excerpt":"With the impact of a $5.6 million non-cash gain from the fair value adjustment of the warrant liability, net income was $0.1 million, or $0.01 per share (basic and diluted) for the three months March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534133/000095017024058730/0000950170-24-058730-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"$0.1 million"},{"label":"EPS","value":"$0.01 per share (basic and diluted)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}